BR112021017774A2 - Dose baixa de citocina coadministrada com irgd para tratar câncer - Google Patents

Dose baixa de citocina coadministrada com irgd para tratar câncer

Info

Publication number
BR112021017774A2
BR112021017774A2 BR112021017774A BR112021017774A BR112021017774A2 BR 112021017774 A2 BR112021017774 A2 BR 112021017774A2 BR 112021017774 A BR112021017774 A BR 112021017774A BR 112021017774 A BR112021017774 A BR 112021017774A BR 112021017774 A2 BR112021017774 A2 BR 112021017774A2
Authority
BR
Brazil
Prior art keywords
irgd
administered
treat cancer
low dose
dose cytokine
Prior art date
Application number
BR112021017774A
Other languages
English (en)
Inventor
Erkki Ruoslahti
Harri Jarvelainen
Original Assignee
Cend Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cend Therapeutics Inc filed Critical Cend Therapeutics Inc
Publication of BR112021017774A2 publication Critical patent/BR112021017774A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

dose baixa de citocina coadministrada com irgd para tratar câncer. métodos e composições compreendendo irgd coadministrado com citocinas para tratar câncer são fornecidos.
BR112021017774A 2019-03-08 2020-03-06 Dose baixa de citocina coadministrada com irgd para tratar câncer BR112021017774A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962815917P 2019-03-08 2019-03-08
PCT/US2020/021570 WO2020185624A1 (en) 2019-03-08 2020-03-06 Low-dose cytokine co-administered with irgd for treating cancer

Publications (1)

Publication Number Publication Date
BR112021017774A2 true BR112021017774A2 (pt) 2021-11-16

Family

ID=72336740

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021017774A BR112021017774A2 (pt) 2019-03-08 2020-03-06 Dose baixa de citocina coadministrada com irgd para tratar câncer

Country Status (9)

Country Link
US (1) US20200282013A1 (pt)
EP (1) EP3934680A4 (pt)
JP (1) JP2022524754A (pt)
KR (1) KR20210142663A (pt)
CN (1) CN113795271A (pt)
AU (1) AU2020235864A1 (pt)
BR (1) BR112021017774A2 (pt)
CA (1) CA3132813A1 (pt)
WO (1) WO2020185624A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021266721A1 (en) * 2020-05-04 2022-12-08 Drugcendr Australia Pty Ltd. Methods for treating pancreatic cancer and other solid tumors
JP2023551771A (ja) * 2020-12-01 2023-12-13 ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク 免疫調節剤を用いて免疫療法に対するがんの感受性を高める方法
WO2022192536A1 (en) * 2021-03-11 2022-09-15 The Methodist Hospital Methods and compositions for treatment of disease
WO2022235852A1 (en) * 2021-05-04 2022-11-10 Cend Therapeutics, Inc. Irgd-analogs and related therapeutic methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001003718A2 (en) * 1999-07-07 2001-01-18 Geltex Pharmaceuticals, Inc. Combination chemotherapy
BRPI1015424B1 (pt) * 2009-06-22 2022-01-18 Burnham Institute For Medical Research Composição compreendendo um elemento cendr e uma co-composição e composição para uso no reforço da internalização, penetração, ou ambas, de uma co-composição
EP3766513A1 (en) * 2011-03-11 2021-01-20 Assistance Publique Hôpitaux de Paris Use of low dosage il-2 for treating vasculitis
WO2014189303A1 (ko) * 2013-05-23 2014-11-27 아주대학교산학협력단 뉴로필린에 특이적인 종양 침투성 펩타이드 및 이 펩타이드가 융합된 융합 단백질
EP3180018B1 (en) * 2014-08-12 2019-07-24 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2 and integrin-binding-fc-fusion protein
WO2017190684A1 (zh) * 2016-05-06 2017-11-09 王牧林 白细胞介素组合及其用途
EP3538130A4 (en) * 2016-11-10 2020-06-03 Nektar Therapeutics IMMUNOTHERAPEUTIC TUMOR TREATMENT PROCEDURE
CN107739410B (zh) * 2017-10-18 2021-07-30 南京鼓楼医院 CD3单链抗体-iRGD融合蛋白、制备及其作为抗肿瘤药物的应用

Also Published As

Publication number Publication date
CA3132813A1 (en) 2020-09-17
AU2020235864A1 (en) 2021-09-30
KR20210142663A (ko) 2021-11-25
US20200282013A1 (en) 2020-09-10
WO2020185624A1 (en) 2020-09-17
EP3934680A4 (en) 2022-12-07
CN113795271A (zh) 2021-12-14
EP3934680A1 (en) 2022-01-12
JP2022524754A (ja) 2022-05-10

Similar Documents

Publication Publication Date Title
BR112021017774A2 (pt) Dose baixa de citocina coadministrada com irgd para tratar câncer
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
WO2019222112A8 (en) Mcl-1 inhibitors
CR20220070A (es) Inhibidores de parp1
PH12020500241A1 (en) Cytokine conjugates for the treatment of autoimmune diseases
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
CL2020002082A1 (es) Inhibidores pd-1/pd-l1.
MX2020008244A (es) Composiciones y metodos para el tratamiento del cancer y de trastornos inmunitarios usando bacterias de veillonella.
CL2017002567A1 (es) Composiciones para modular la expresión de c9orf72
MX2018008052A (es) Inhibidores de desmetilasa especifica de lisina 1 (lsd1).
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
EP4252851A3 (en) Ezh2 inhibitors for treating lymphoma
PH12019502049A1 (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors
MX2022002337A (es) Polipéptidos de tff2 modificados.
MX2020010116A (es) Compuestos macrociclicos como inhibidores de quinasas del receptor de tropomiosina (trk).
CL2017002765A1 (es) El uso de estimuladores sgc, activadores gc, solos y combinaciones con inhibidores pde5 para el tratamiento de úlceras digitales (du) concomitante con esclerosis sistémica (ssc).
MX2018005825A (es) Celulas inmunes modificadas y usos de las mismas.
MX2021016050A (es) Formulaciones transdermicas.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2022006312A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
EA202190201A1 (ru) Составы для уменьшения размера опухоли и способы их применения
MX2020005344A (es) Compuestos de pirazolopiridinona.
MX2021012813A (es) Conjugados de citocina de liberacion lenta.